Hysterosalpingography (HSG) and hysterosalpingo-foam sonography are two methods to assess tubal patency during fertility work-up. This study aims to investigate the effectiveness of tubal flushing with oil-based contrast during HSG compared to tubal flushing during HyFoSy in women undergoing fertility work-up. The hypothesis is that tubal flushing with oil-based contrast during HSG leads to more live births than tubal flushing during HyFoSy.
Background: The diagnostic work-up for infertility generally includes estimating the risk for tubal pathology and if indicated assessing tubal patency. Traditionally, tubal patency testing during the fertility work-up is performed with hysterosalpingography (HSG). In previous studies it has been demonstrated that tubal flushing with oil-based contrast during HSG resulted in more ongoing pregnancies than when HSG is performed with water-based contrast. HyFoSy is a more patient friendly alternative for HSG. Up till now, the fertility enhancing effect of tubal flushing with ExEm Foam during HyFoSy has only been studied in relatively small and observational studies. Objectives:The main objective of this study is to determine whether tubal flushing with oil-based contrast during HSG results into more pregnancies leading to live births when compared to tubal flushing with ExEm Foam during HyFoSy, and whether this approach is cost-effective. In this study the safety of both strategies will also be compared. Rationale: The hypothesis is that tubal flushing with oil-based contrast during HSG leads to more live births compared to tubal flushing with ExEm Foam during HyFoSy in women with an indication for tubal patency testing. If more live births are achieved, expensive fertility treatments will be less needed, which makes tubal flushing with oil-based contrast during HSG a cost-effective strategy. Study design: This study is a multicenter randomized controlled trial with an economic analysis alongside it. Women with indication for tubal patency testing will be randomized to tubal flushing with oil-based contrast during HSG and tubal flushing with ExEm Foam during HyFoSy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
AmsterdamUMC
Amsterdam, Netherlands
RECRUITINGNumber of pregnancies leading to live birth.
Pregnancy is defined as a positive pregnancy test, increase in human chorionic gonadotropin (HCG) level or a pregnancy shown on ultrasonographic examination. Live birth is defined as the birth of live baby born beyond 24 weeks of pregnancy.
Time frame: within six months after randomization
Time to pregnancy leading to live birth
Calculated from the day of randomization till the first day of the last menstrual bleeding before a positive pregnancy test.
Time frame: within six months after randomization
Number of clinical pregnancies
Clinical pregnancy is defined as gestational sac with or without heartbeat visible on ultrasound.
Time frame: within six months after randomization
Number of miscarriages
Miscarriage is defined as presence of non-vitality on ultrasound or spontaneous loss off pregnancy
Time frame: within six months after randomization
Number of multiple pregnancies
Multiple pregnancy is defined as two or more vital intrauterine pregnancies at 12 weeks gestation.
Time frame: within six months after randomization
Number of ectopic pregnancies
Ectopic pregnancy is defined as no intrauterine gestational sac with: an ectopic gestational sac OR HCG concentration \>1500 international units per liter (IU/L) with free fluid/ectopic mass on ultrasound or serum HCG \>2000IU/L without free fluid/ectopic mass on ultrasound
Time frame: within six months after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
NONE
Enrollment
1,102
Number of adverse events
e.g. infection, intravasation, thyroid dysfunction
Time frame: within one months after tubal patency testing
Procedural pain scores
measured by Visual Analogue Scale (VAS) on a scale from 0.0 to 10.0 centimeter immediately after tubal patency testing.
Time frame: Within 15 minutes after tubal patency testing
Number of fertility treatment cycles
e.g. intra uterine insemination, in vitro fertilization, intracytoplasmatic sperm injection
Time frame: within six months after randomization
Number of pregnancy complications
e.g. pregnancy induced hypertension, fetal growth restriction, still birth.
Time frame: within six months after randomization
Cost-effectiveness
Comparing the costs (including costs for tubal patency testing and additional fertility treatments) and the effects (chance of live birth)
Time frame: within six months after randomization